What is MiNA Therapeutics?
Founded in 2008, MiNA Therapeutics is a clinical-stage biotechnology company headquartered in London, dedicated to the development of RNA activation (RNAa) therapeutics. Unlike traditional gene silencing approaches, the company's platform utilizes small activating RNAs to upregulate gene expression, offering a novel therapeutic modality for diseases that have historically been considered undruggable. The company's core focus remains on oncology, specifically liver cancer, where it seeks to provide transformative treatment options for patients with limited alternatives. By integrating advanced molecular biology with a robust drug discovery engine, MiNA Therapeutics has established itself as a critical player in the next generation of genetic medicine, bridging the gap between academic innovation and commercial-scale pharmaceutical development.
How much funding has MiNA Therapeutics raised?
MiNA Therapeutics has raised a total of $90.2M across 3 funding rounds:
Private Equity
$45.2M
Series A
$30M
Private Equity
$15M
Private Equity (2017): $45.2M with participation from Sosei Group Corporation
Series A (2020): $30M led by aMoon
Private Equity (2021): $15M supported by Eli Lilly and Company Pvt
Key Investors in MiNA Therapeutics
Sosei Group Corporation
An international biopharmaceutical group specializing in GPCR-targeted drug discovery and structure-based design, with a deep pipeline across neurology and immunology.
aMoon
A prominent venture capital firm focused on health-tech and life sciences, providing strategic support to companies at the intersection of biology and technology.
Eli Lilly and Company Pvt
The Indian subsidiary of the global biopharmaceutical giant, focused on delivering advanced treatment options for chronic diseases including diabetes and various forms of cancer.
What's next for MiNA Therapeutics?
Looking ahead, the strategic deployment of the $15M will likely focus on expanding the clinical footprint of MiNA Therapeutics' lead candidates. The company is expected to prioritize the optimization of its RNAa platform to enhance delivery mechanisms and therapeutic efficacy. Furthermore, the involvement of major pharmaceutical partners suggests a potential trajectory toward collaborative co-development agreements or licensing opportunities that could validate the platform's utility across diverse therapeutic areas. As the company matures, the focus will shift from early-stage discovery to establishing a sustainable commercial pipeline, ensuring that its innovative RNA activation technology can be effectively translated into standard-of-care treatments for chronic and life-threatening conditions.
See full MiNA Therapeutics company page
